雄激素剥夺疗法与后续角膜炎风险
Androgen deprivation therapy and the risk of subsequent keratitis.
作者信息
Liu Dai-Wei, Hsu Ren-Jun, Huang Sheng-Yao, Liao Yen-Hsiang, Wu Chen-Ta, Hsu Wen-Lin
机构信息
Department of Radiation Oncology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.
School of Medicine, Tzu Chi University, Hualien, Taiwan.
出版信息
Tzu Chi Med J. 2020 Dec 4;33(1):55-60. doi: 10.4103/tcmj.tcmj_31_20. eCollection 2021 Jan-Mar.
OBJECTIVES
The objective of the study was to determine the risk of subsequent keratitis in prostate cancer (PCa) patients treated with androgen deprivation therapy (ADT).
MATERIALS AND METHODS
Three thousand three hundred and nine patients with PCa were identified using data from Taiwan's National Health Insurance Research Database for 2001 through 2013. Among those patients, 856 treated with ADT comprised the study group, while 856 non-ADT-treated patients matched with 1:1 propensity-score-matched analysis comprised the control group. The demographic characteristics and comorbidities of all the patients were analyzed, and Cox proportional hazards regression was utilized to determine the hazard ratios (HRs) for subsequent keratitis.
RESULTS
A total of 157 (9.2%) patients had newly diagnosed keratitis. Compared to the non-ADT-treated patients, the ADT-treated patients had a reduced risk of subsequent keratitis, with an adjusted HR of 0.38 (95% confidence interval: 0.27-0.55; < 0.001).
CONCLUSION
ADT treatment apparently decreased the risk of subsequent keratitis in the investigated PCa patients, but the clinical significance of this finding should be further assessed in additional studies.
目的
本研究的目的是确定接受雄激素剥夺疗法（ADT）治疗的前列腺癌（PCa）患者发生继发性角膜炎的风险。
材料与方法
利用台湾国民健康保险研究数据库2001年至2013年的数据，确定了3309例PCa患者。其中，856例接受ADT治疗的患者组成研究组，856例未接受ADT治疗的患者通过1:1倾向评分匹配分析组成对照组。分析了所有患者的人口统计学特征和合并症，并采用Cox比例风险回归分析来确定继发性角膜炎的风险比（HRs）。
结果
共有157例（9.2%）患者新诊断为角膜炎。与未接受ADT治疗的患者相比，接受ADT治疗的患者发生继发性角膜炎的风险降低，校正后的HR为0.38（95%置信区间：0.27-0.55；P<0.001）。
结论
ADT治疗明显降低了所研究的PCa患者发生继发性角膜炎的风险，但这一发现的临床意义应在更多研究中进一步评估。
Zotero 插件